Pugsy wrote:The studies that got everyone in panic mode about using ASV weren't ideal studies IMHO.
Small group of people used...those people were already really sick with CHF and ejection rates below 45 and they didn't use the machine even 4 hour average.
So they took some people who were really sick and didn't come close to using the machine all night and the end result was an increase in chance of mortality.. Was it because they were really sick in the first place with a bad heart...or was it because they didn't use the machine for anywhere near recommended hours of us or was it because ASV triggered something to make a bad situation worse???
Would this group of really sick people maybe had a better mortality rate if they had used the machine all night??? We don't know.
They did have a reasonable control group. Here is a summary of that study from a recent review at UpToDate.com:
Increased caution when considering the use of ASV in patients with heart failure is based on results of SERVE-HF, a multicenter, open-label trial that randomly assigned 1325 patients with moderate to severe predominant CSA (AHI ≥15, central apnea index >10) and symptomatic heart failure (defined as an EF ≤45 percent and New York Heart Association [NYHA] Class III, NYHA class IV, or NYHA class II with ≥1 hospitalization for heart failure in the previous 24 months) to ASV plus standard medical therapy or medical therapy alone [16]. The primary endpoint was death from any cause, lifesaving cardiovascular intervention (cardiac transplantation, implantation of a ventricular assist device, resuscitation after sudden cardiac arrest, or appropriate lifesaving shock), or unplanned hospitalization for worsening heart failure. Secondary endpoints included time to death from any cause, time to death from cardiovascular causes, change in NYHA class, and change in timed-walk distance. Results included the following:
●The mean age of the patients was 69 years, and approximately 90 percent were male. The majority of patients had NYHA class III heart failure, and the mean ejection fraction was 32 percent. Approximately 50 percent of the patients in both groups had an implanted defibrillator device. The mean baseline AHI in the two treatment groups was 31 to 32 events per hour, and central AHI to total AHI ratio was 81 to 82 percent.
●ASV effectively reduced the number of apneas and hypopneas as measured by polysomnography: the mean AHI in the ASV group decreased from 31 events per hour at baseline to 6.6 events per hour at 12 months.
●The incidence of the primary endpoint was similar in the ASV group compared with controls (54 versus 51 percent; hazard ratio [HR] 1.13, 95% CI 0.97-1.31). In addition, ASV did not improve symptoms or ejection fraction.
●Compared with controls, patients assigned to ASV had significantly higher all-cause mortality (35 versus 29 percent; HR 1.28, 95% CI 1.06-1.55) and cardiovascular mortality (30 versus 24 percent; HR 1.34, 95% CI 1.09-1.65).
The mechanism whereby ASV led to an increase in mortality in this trial is not known. One possibility is that ASV led to a decrease in cardiac output and stroke volume in susceptible patients, such as those with low preload. Another possibility is that Cheyne-Stokes respiration serves a compensatory function in heart failure, and that ASV proved detrimental by diminishing this compensatory respiratory pattern [17,18].
The
same author encourages caution for ASV use even in those without heart failure and low EF:
ASV remains an option in patients with hyperventilation-related CSA and a preserved ejection fraction, although treatment decisions in such patients should be individualized, and there is a paucity of direct data in these patients [15].
Patients who are already using ASV for other indications (eg, heart failure with preserved ejection fraction, primary CSA, treatment-emergent CSA) should be informed about the safety signal from the SERVE-HF trial; in some cases the balance of risks and benefits may still favor ASV therapy, particularly in patients who are responding to therapy and have failed prior CPAP.
From a
different author but relevant:
Although there is not a universally accepted definition of continuous positive airway pressure (CPAP) "failure" in a setting of treatment of central sleep apnea (CSA), we define it as the residual apnea-hypopnea index (AHI) of 5 or above, with >50 percent of residual events of central origin.
So if I were the OP, I would not consider this a CPAP failure and would have concerns about a change to ASV.